Compounders Research Compare

Crescent Biopharma, Inc.(CBIO)

Biotechnology · Waltham, MA

$14.28+0.34 (+2.44%)

Delayed quote: Oct 6, 2026, 10:15 AM EDT

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Waltham, MA

44 employees

crescentbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joshua T. Brumm

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:16:05.023Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:16:05.023Z.

Quote observation: 2026-10-06T14:15:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 530,415,463
Total debt · period ending 2026-06-30: 1,437,000
Cash · period ending 2026-06-30: 171,593,000
TTM operating EBITDA · period ending 2026-06-30: -168,258,000

FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBIO EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CBIO Competitors' EV/EBITDA Ratio

Crescent Biopharma, Inc.

Current

Market Cap

$530.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$526.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$525.15M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$537.16M

EV/EBITDA Ratio

N/A

TTM Avg

144.36x

3Y Avg

144.36x

5Y Avg

144.36x

Altimmune, Inc.

Market Cap

$515.36M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$510.90M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Allogene Therapeutics, Inc.

Market Cap

$503.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CytomX Therapeutics, Inc.

Market Cap

$549.35M

EV/EBITDA Ratio

N/A

TTM Avg

13.55x

3Y Avg

10.69x

5Y Avg

10.69x

MiniMed Group, Inc.

Market Cap

$560.00M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aquestive Therapeutics, Inc.

Market Cap

$562.72M

EV/EBITDA Ratio

N/A

TTM Avg

42.12x

3Y Avg

42.12x

5Y Avg

42.12x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Crescent Biopharma, Inc. (CBIO)	$530.42M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$526.07M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$525.15M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$537.16M	N/A	144.36x	144.36x	144.36x
Altimmune, Inc. (ALT)vs ›	$515.36M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$510.90M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$503.41M	N/A	N/A	N/A	N/A
CytomX Therapeutics, Inc. (CTMX)vs ›	$549.35M	N/A	13.55x	10.69x	10.69x
MiniMed Group, Inc. (MMEDV)vs ›	$560.00M	N/A	N/A	N/A	N/A
Aquestive Therapeutics, Inc. (AQST)vs ›	$562.72M	N/A	42.12x	42.12x	42.12x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics